AYOXXA to develop multiplex immunoassay to support treatment of sepsis patients

AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company’s innovative bead-based protein analysis platform LUNARIS™.

As a result of the research project, the multiplex assay will be available as a commercial detection kit. It will be marketed initially for use in academic and preclinical research and, after further validation, for routine use in the clinic in the medium term.

The project is funded by the "European Regional Development Fund" (ERDF) and comprises a consortium of North Rhine-Westphalian companies, university hospitals and universities. Head of the project is Prof. Michael Adamzik from the Ruhr University Bochum and the University Hospital Bochum, Department of Anesthesiology, Intensive Care and Pain Therapy. The duration of the project is set for three years.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AYOXXA Biosystems GmbH. (2019, June 18). AYOXXA to develop multiplex immunoassay to support treatment of sepsis patients. News-Medical. Retrieved on June 19, 2019 from https://www.news-medical.net/news/20180420/AYOXXA-to-develop-multiplex-immunoassay-to-support-treatment-of-sepsis-patients.aspx.

  • MLA

    AYOXXA Biosystems GmbH. "AYOXXA to develop multiplex immunoassay to support treatment of sepsis patients". News-Medical. 19 June 2019. <https://www.news-medical.net/news/20180420/AYOXXA-to-develop-multiplex-immunoassay-to-support-treatment-of-sepsis-patients.aspx>.

  • Chicago

    AYOXXA Biosystems GmbH. "AYOXXA to develop multiplex immunoassay to support treatment of sepsis patients". News-Medical. https://www.news-medical.net/news/20180420/AYOXXA-to-develop-multiplex-immunoassay-to-support-treatment-of-sepsis-patients.aspx. (accessed June 19, 2019).

  • Harvard

    AYOXXA Biosystems GmbH. 2019. AYOXXA to develop multiplex immunoassay to support treatment of sepsis patients. News-Medical, viewed 19 June 2019, https://www.news-medical.net/news/20180420/AYOXXA-to-develop-multiplex-immunoassay-to-support-treatment-of-sepsis-patients.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post